Dasatinib and chronic myeloid leukemia: Two-year follow-up in eight clinical trials

Clinical Lymphoma and Myeloma

Volumn 9, Issue 6, 2009, Pages 417-424

  Pavlů, Jiří ^a   Marin, David ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

BCR ABL; Imatinib intolerance; Imatinib resistance; Tyrosine kinase inhibitors

Indexed keywords

DASATINIB; IMATINIB;

ABDOMINAL PAIN; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ASTHENIA; BLEEDING; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 72549086626     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.083     Document Type: Review

References (38)

1. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26:3358-3363
2. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS- 354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66:5790-5797
3. Khorashad JS, Thelwell N, Milojkovic D, et al. A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia. J Clin Pathol 2008; 61:863-865
4. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-4505
5. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
6. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108:2332-2338
7. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood 2007; 110:2242-2249
8. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27:469-471
9. Khorashad JS, Milojkovic D, Mehta P, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008; 111:2378-2381
10. Kamath AV, Wang J, Lee FY, et al. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2007; 61:365-376
11. Wang L, Christopher LJ, Cui D, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 2008; 36:1828-1839
12. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomepositive leukemia. Blood 2008; 112:1005-1012
13. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-2541 (Pubitemid 43882349)
14. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22:1200-1206
15. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109:5143-5150 (Pubitemid 46890528)
16. Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (STARTR). Cancer 2009; 115:4136-4147
17. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in he Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. J Clin Oncol 2009; 27:3472-3479
18. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109:4143-4150 (Pubitemid 46743375)
19. Guilhot F, Apperley JF, Kim DW, et al. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood 2007; 110:145a (abstract 470).
20. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109:3207-3213
21. Gambacorti C, Cortes J, Kim DW, et al. Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program. Blood 2007; 110:145a (abstract 472).
22. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosomepositive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood 2007; 110:2309-2315
23. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26:3204-3212
24. Shah NP, Kim DW, Kantarjian HM, et al. Dasatinib dose-optimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose. Blood 2008; 112:1107 (abstract 3225).
25. Kantarjian H, Kim DW, Dorlhiac-Llacer PE, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) In patients with accelerated phase chronic myeloid leukemia (CML-AP): 2-year follow-up data from CA180-035. Blood 2008; 112:1106 (abstract 3224).
26. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009; 113:6322-6329
27. Larson RA, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with imatinib-resistant or -intolerant Philadelphia chromosomepositive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035. Blood 2008; 112:1006 (abstract 2926).
28. Saglio G, Kantarjian H, Hochhaus A, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-Year Data from CA180-035. Blood 2008; 112:1107 (abstract 3226).
29. Khoury HJ, Goldberg SL, Mauro MJ, et al. Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CMLCP) intolerant to imatinib: a retrospective analysis of safety. J Clin Oncol 2008; 26:375s (abstract 7015).
30. Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14:485-493
31. Stone RM, Kantarjian HM, Baccarani M, et al. Efficacy of dasatinib in patientsto imatinib: 2-year follow-up data from START-C (CA180-013). Blood 2007; 110:225a (abstract 734).
32. Porkka K, Martinelli G, Ottman OG, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L. Haematologica 2008; 93(s1):1 (abstract 0001).
33. Porkka K, Simonsson B, Dombret H, et al. Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180- 015). Blood 2007; 110:826a-7a (abstract 2810).
34. Hochhaus A, Mueller MC, Cortes J, et al. Dasatinib efficacy after imatinib failure by dosing schedule and baseline BCR-ABL mutation status in patients with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica 2008; 93(s1):371 (abstract 0933).
35. Cortes J, Kim DW, Guilhot F, et al. Dasatinib (SPRYCEL) in patients with chronic myelogenous leukemia in accelerated phase that is imatinib-resistant or -intolerant: updated results of the CA180-005 START-A phase II study. Blood 2006; 108:613a (abstract 2160).
36. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinibresistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22:2176-2183
37. Hochhaus A, Kim DW, Rousselot P, et al. Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: results from a randomized phase-III trial (CA180034). Haematologica 2007; 92(s1):128-129 (abstract 0359).
38. Ottmann O, Hochhaus A, Saglio G, et al. Dasatinib induces rapid and durable responses in patients with Ph+ ALL resistant or intolerant to imatinib: updated results from CA180015 (START-L) trial. Haematologica 2007; 92(s1):9-10 (abstract 0026).